NAD+: The Coenzyme That Declines With Age, and What Raising It Actually Shows

The short version

NAD+ stands for nicotinamide adenine dinucleotide. It is not a peptide but a coenzyme — a molecular partner that participates in hundreds of cellular reactions. Two roles make it relevant to aging research. First, it is the cell's primary electron carrier in energy metabolism: glycolysis, the TCA cycle, and oxidative phosphorylation all depend on cycling between the oxidized form (NAD+) and the reduced form (NADH) to make ATP. Second, NAD+ is consumed as a substrate by three families of enzymes — sirtuins, PARPs, and CD38 — that regulate DNA repair, gene expression, and inflammation ^[11].

The relevant aging fact is that tissue NAD+ declines with age, partly because the NAD-consuming ectoenzyme CD38 rises. The argument for supplementing with precursors such as NMN or NR is that restoring NAD+ might restore the function of those downstream enzymes. Human RCTs have now shown that oral NMN and NR reliably raise blood NAD+, with one multicenter double-blind trial finding dose-dependent increases at 300-900 mg/day NMN ^[9] and a placebo-controlled NR study showing 22-142% dose-dependent NAD+ elevation ^[12]. What remains harder to demonstrate is whether elevated blood NAD+ in a healthy middle-aged person translates to meaningful clinical aging endpoints — a 2025 Nature Metabolism review concluded that human efficacy data are still limited and tissue-specific NAD+ data remain sparse ^[8]. This page reports what the studies found; it does not advise on any dose or regimen.

What it is

NAD+ is a dinucleotide: nicotinamide mononucleotide (NMN) and adenosine monophosphate (AMP) joined by two bridging phosphate groups, with a pyridine nicotinamide ring on one side and an adenine ring on the other. Molecular formula C21H27N7O14P2. The oxidized form is NAD+; the reduced form is NADH. It is an endogenous molecule present in every cell of the body. It is not a synthetic research-only compound — it is sold as a dietary supplement and used in IV/injectable wellness therapy, though compounded injectable NAD+ carries its own regulatory and safety considerations distinct from oral precursors ^[11].

Precursors NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the forms most studied in human RCTs because oral NAD+ itself is not efficiently absorbed intact. NR's regulatory status as a dietary supplement has been established for years; NMN's has been actively contested by the FDA, which has asserted it is excluded from the dietary-supplement definition because it was first investigated as a drug ^[8].

How it works

NAD+ operates through two converging roles.

Redox carrier. In glycolysis, the TCA cycle, and the mitochondrial electron-transport chain, NAD+ accepts electrons from metabolic intermediates to form NADH, which then donates those electrons to complex I to drive ATP synthesis. This shuttle is essential for aerobic respiration: without cycling NAD+ back from NADH, glycolysis and the TCA cycle grind to a halt.

Signaling substrate. Three enzyme families consume NAD+ (rather than reversibly cycling it) as a substrate: sirtuins (SIRT1-7), which deacylate histones and other proteins to regulate gene expression and stress responses; PARP1, which uses NAD+ to build poly(ADP-ribose) chains at sites of DNA damage; and CD38/CD157, NAD-consuming ectoenzymes that rise with age and inflammation. When NAD+ is depleted, all three systems are substrate-limited — the hypothesis being that restoring NAD+ reactivates sirtuin, DNA-repair, and anti-inflammatory activity that falters with aging ^[11].

Why does NAD+ decline with age? CD38 activity increases with age and chronic inflammation, consuming a growing fraction of the NAD+ pool. NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting salvage enzyme that recycles nicotinamide back into NAD+, may also decrease. The result is a smaller pool competing among the same enzyme consumers ^[11].

What the research shows

Human RCT — NMN dose-response. In a multicenter, double-blind, placebo-controlled, parallel-group trial of 80 healthy middle-aged adults, oral NMN at 300, 600, or 900 mg/day for 60 days raised blood NAD+ in a dose-dependent manner at both day 30 and day 60 across all NMN groups versus placebo (p ≤ 0.001), with 600 mg/day identified as optimal. Walking distance and quality-of-life scores also improved versus placebo; no safety issues emerged at any dose ^[9].

Human RCT — NMN in prediabetic women. Ten weeks of oral NMN (250 mg/day) significantly improved skeletal muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp in prediabetic postmenopausal women; body composition and HbA1c did not change ^[10]. This is among the more mechanistically specific human results — it moved a downstream functional endpoint, not only blood NAD+.

Human RCT — NR dose-response. Nicotinamide riboside at 100-1000 mg/day for 8 weeks raised whole-blood NAD+ dose-dependently — by 22%, 51%, and 142% respectively — in healthy overweight adults, with no flushing and no significant adverse-event differences from placebo; LDL cholesterol was not elevated ^[12]. This confirms NR as a well-tolerated NAD+ booster across a wide dose range.

Foundational mechanism review. A 2021 Nature Reviews Molecular Cell Biology synthesis established the framework: age-related NAD+ decline across yeast, worm, mouse, and human models; the three consuming enzyme families and their competition for the NAD+ pool; and the rationale for precursor supplementation as a candidate anti-aging strategy ^[11].

2025 state-of-the-field review. A 2025 Nature Metabolism narrative review of human clinical evidence on NAD+ precursor supplementation in aging concluded that blood NAD+ elevation is consistent and reproducible, but that age-related NAD+ decline has been confirmed in only a limited number of human studies, that tissue-specific NAD+ data remain sparse, and that translation to clinical endpoints in aging is inconsistent — underscoring the need for more rigorous human trials ^[8].

Reported effects, cautions & safety

NAD+ precursor supplementation has been studied in human trials sufficiently to characterize a safety profile, which is better established than for most research peptides. The cautions, however, are also more precisely defined:

Cautions from the cited literature:

• Oral NAD+ itself is ineffective as a supplement. Oral NAD+ is poorly absorbed intact by cells; the rational approach is oral precursors (NMN or NR), and supplements sold simply as "NAD+" capsules are largely considered ineffective at raising intracellular NAD+ ^[8].
• Blood NAD+ elevation does not equal clinical aging benefits. Consistently raising blood NAD+ in healthy adults is now well established. Whether that change prevents age-related disease, extends healthspan, or produces measurable longevity benefits in humans is not established; the 2025 Nature Metabolism review explicitly characterizes the clinical translation as limited ^[8].
• Animal-to-human extrapolation gap. Most of the dramatic anti-aging data — reversal of muscle aging, improved cognition, extended lifespan — come from rodents. Human results are more modest and variable ^[8].
• IV NAD+ wellness therapy risks. Compounded injectable NAD+ infusions are marketed aggressively but rest on minimal controlled evidence. Infused NAD+ is rapidly cleared from plasma, and infusions run too quickly can cause chest discomfort, abdominal cramps, flushing, and nausea. The FDA has issued a Class I recall of a compounded NAD+ injection for elevated bacterial endotoxin contamination ^[8].
• Theoretical cancer caution. NAD+ supports proliferating cells; a theoretical concern exists that boosting NAD+ could fuel the metabolism of existing cancers. NAD+ in oncology has dual, context-dependent roles, and caution is advised in any cancer-relevant population ^[11].
• NMN regulatory uncertainty. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a drug, creating marketplace uncertainty ^[8].
• Supplement quality variation. Supplement-grade products vary widely in purity and actual content; third-party testing is not guaranteed.

Where it fits in longevity research

NAD+ is the most broadly human-tested compound on this desk. Its RCT base on blood NAD+ elevation is robust, and the 2021 muscle-insulin-sensitivity result ^[10] stands as one of the field's cleaner demonstrations of a downstream functional effect in a human trial. But the headline longevity claim — that restoring NAD+ extends healthspan or reverses aging in people — is not yet supported by long-term human data; the strongest evidence for that story remains in rodents and mechanisms. Alongside Epitalon, whose claims are more dramatic but whose evidence base is narrower and less independently replicated, NAD+ represents the more mature clinical story in this pair: more controlled trials, better-characterized safety, and a more explicit acknowledgment of the gap between mechanistic plausibility and demonstrated human benefit. See the comparison page for a side-by-side view.